Pyrrolopyrimidines as CFTR potentiators

Pyrrolopyrimidines as CFTR potentiators

PYRROLOPYRIMIDINES AS CFTR POTENTIATORS Abstract Ra H 4 N z Rib The present invention relates to compounds of Formula (I), wherein Ra, Rlb, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MATHIAS, John Paul, ZAPF, Christoph Wolfgang, THORARENSEN, Atli, STROHBACH, Joseph Walter, EFREMOV, Ivan Viktorovich, LIMBURG, David Christopher, DENNY, Rajiah Aldrin, GAVRIN, Lori Krim, ELBAUM, Daniel
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PYRROLOPYRIMIDINES AS CFTR POTENTIATORS Abstract Ra H 4 N z Rib The present invention relates to compounds of Formula (I), wherein Ra, Rlb, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjogren's Syndrome, and other CFTR associated disorders.